Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ImClone Board Members Demand Control Premium From Icahn

This article was originally published in The Pink Sheet Daily

Executive Summary

Latest salvo from Icahn prompts board to ask shareholders to reject billionaire’s demands.

You may also be interested in...



Billionaire Icahn Named ImClone Chairman, Interim CEO Resigns

Firm searches for new CEO with biotech, drug development and commercialization experience.

Billionaire Icahn Named ImClone Chairman, Interim CEO Resigns

Firm searches for new CEO with biotech, drug development and commercialization experience.

Icahn Gets Wish With Departure Of ImClone’s Kies, But Will Door Open To Him?

Billionaire and his allies hold 40% of the biotech’s board, possibly leading to further changes.

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel